All In Biotech

Drug Trial Radar · NCT02541383

A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

Study of Daratumumab in Combination With Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD) in the First Line Treatment of Transplant Eligible Subjects With Newly Diagnosed Multiple Myeloma

Last checked: Nov 20, 2026Latest source record: Apr 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. Randomized with 1,085 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,085

Actual

Start

Sep 2015

Primary completion

Aug 27, 2020

Study completion Sep 1, 2023

Sponsor

Lead sponsor
Intergroupe Francophone du MyelomeResearch network
Sponsor type
Research network
Collaborators
HOVON - Dutch Haemato-Oncology Association; Janssen Research & Development, LLC
First posted
Sep 4, 2015

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate if the addition of daratumumab to Bortezomib, Thalidomide and Dexamethasone will increase the stringent complete response rate after consolidation therapy and increase the progression free survival after daratumumab maintenance therapy in transplant eligible participants with previously untreated Multiple Myeloma.

Conditions

  • Multiple Myeloma

Interventions

  • Bortezomib (VELCADE), Thalidomide, and Dexamethasone (VTD)Drug

    Part 1: 4 Cycles of Bortezomib,Thalidomide and Dexamethasone induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone consolidation

  • Bortezomib, Thalidomide, Dexamethasone (VTD) + daratumumabDrug

    Part 1: 4 Cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16mg/kg induction therapy, followed by Autologous Stem Cell Transplantation, followed by 2 cycles of Bortezomib, Thalidomide and Dexamethasone plus daratumumab 16 mg/kg consolidation

  • DaratumumabDrug

    Daratumumab 16mg/kg every 8 weeks for 2 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Post-Consolidation Stringent Complete Response (sCR) RateTime frame: At day 100 post Autologous Stem Cell Transplant (ASCT), up to 114 days post ASCT
  2. Progression Free Survival (PFS) Post Completion of Maintenance TherapyTime frame: From the date of second randomization to either progressive disease or death which ever occurred first, with a median follow-up time of 35.4 months (cut-off for analysis was 26 months after the last rando 2 date).

Locations

107 sites in 3 countries. Site status is shown where the registry gives one.

  • BE-Antwerp-ZNA Stuivenberg

    Antwerp, Belgium

  • AZ St Jan Brugge Oostende AV

    Bruges, Belgium

  • Institut Jules Bordet

    Brussels, Belgium

  • UCL Saint-Luc

    Brussels, Belgium

  • UZ Brussel

    Brussels, Belgium

  • GHDC

    Charleroi, Belgium

  • UZ Gent

    Ghent, Belgium

  • CH Jolimont

    La Louvière, Belgium

  • University Hospital Leuven

    Leuven, Belgium

  • Domaine Universitaire du Sart Tilman

    Liège, Belgium

  • AZ Delta

    Roeselare, Belgium

  • AZ Turnhout

    Turnhout, Belgium

  • UCL Mont-Godinne

    Yvoir, Belgium

  • CHU Amiens Sud

    Amiens, France

  • CHRU-Hôpital du Bocage

    Angers, France

  • Centre Hospitalier d'Argenteuil Victor Dupouy

    Argenteuil, France

  • Centre Hospitalier H.Duffaut

    Avignon, France

  • Centre hospitalier de la Côte Basque

    Bayonne, France

  • Hôpital Jean Minjoz

    Besançon, France

  • Hôpital Avicenne

    Bobigny, France

  • Polyclinique Bordeaux Nord Acquitaine

    Bordeaux, France

  • Hôpital de Fleyriat

    Bourg-en-Bresse, France

  • CHRU Brest - Hôpital A. Morvan

    Brest, France

  • CHU Caen - Côte de Nacre

    Caen, France

  • Clinique du Parc

    Castelnau-le-Lez, France

  • CH René Dubos

    Cergy-Pontoise, France

  • Hôpital Privé Sévigné

    Cesson-Sévigné, France

  • Centre Hospitalier William Morey

    Chalon-sur-Saône, France

  • CH Chambéry

    Chambéry, France

  • Hôpital d'Instruction des Armées Percy

    Clamart, France

  • CHU d'Estaing

    Clermont-Ferrand, France

  • Centre Hospitalier Sud Francilien

    Corbeil-Essonnes, France

  • CHU Henri Mondor

    Créteil, France

  • CHRU Dijon - Hôpital des Enfants

    Dijon, France

  • Centre Hospitalier Général

    Dunkirk, France

  • CHRU Hôpital A. Michallon

    Grenoble, France

  • CHD Vendée

    La Roche-sur-Yon, France

  • CHV André Mignot - Université de Versailles

    Le Chesnay, France

  • CH de Chartres - Hôpital Louis Pasteur

    Le Coudray, France

  • Centre Hospitalier

    Le Mans, France

Showing 40 of 107 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.